</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
CB Partner Webinar 1 hour Boehringer Ingelheim {{webinarsautomatedemailsregistrationconfirmation::client_only_logo}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_self_hosted}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_alt}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_width}} {{webinarsautomatedemailsregistrationconfirmation::client_only_logo_custom_css}} {{webinarsautomatedemailsregistrationconfirmation::client_color}} {{webinarsautomatedemailsregistrationconfirmation::supported_by}} This webinar will explore new research in sodium-glucose cotransporter-2 (SGLT2) inhibitors, a mainstay treatment for human diabetics that holds promise for diabetic cats. The mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors and their role in treating feline diabetes mellitus The efficacy of velagliflozin, an SGLT2 inhibitor, in diabetic cats with regard to glycemic parameters and clinical signs Adverse effects of velagliflozin in diabetic cats {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_4}} {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_5}} {{webinarsautomatedemailsregistrationconfirmation::learning_objectives_bullet_6}}
Dear #FIRSTNAME#,
Thank you for registering for "#EVENTTITLE#," sponsored by Boehringer Ingelheim. Thank you for registering for "#EVENTTITLE#."
This webinar will explore new research in sodium-glucose cotransporter-2 (SGLT2) inhibitors, a mainstay treatment for human diabetics that holds promise for diabetic cats.
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Learning Objectives
  • The mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors and their role in treating feline diabetes mellitus
  • The efficacy of velagliflozin, an SGLT2 inhibitor, in diabetic cats with regard to glycemic parameters and clinical signs
  • Adverse effects of velagliflozin in diabetic cats
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Webinar Details
#EVENTDAY#, #EVENTDATE#  |  #EVENTTIME# #EVENTTIMEZONESHORT#  |  1 hour
Sponsored by Boehringer Ingelheim
Add to Your Calendar
Use the links below to add to your calendar. We'll also send a couple reminders in advance of the webinar.
#CALENDARREMINDER#
How to Join the Webinar
Click the link below to join the webinar. You can join up to 15 minutes before the start time.
#AUDIENCEURL#
Once you click the link, you may be prompted to sign in with the email you used to register (#EMAIL#).
Thank you for registering! We look forward to seeing you.
Sincerely,
The Clinician's Brief Team
The Boehringer Ingelheim Team
</head> <body style="-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;margin:0;min-width:100%;padding:0;width:100%" data-bg-color="#E9EBF2" bgcolor="#E9EBF2">
Dear #FIRSTNAME#,
Thank you for registering for "#EVENTTITLE#," sponsored by Boehringer Ingelheim. Thank you for registering for "#EVENTTITLE#."
This webinar will explore new research in sodium-glucose cotransporter-2 (SGLT2) inhibitors, a mainstay treatment for human diabetics that holds promise for diabetic cats.
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Learning Objectives
  • The mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors and their role in treating feline diabetes mellitus
  • The efficacy of velagliflozin, an SGLT2 inhibitor, in diabetic cats with regard to glycemic parameters and clinical signs
  • Adverse effects of velagliflozin in diabetic cats
If you have any questions for our speaker, you can direct them to support@cliniciansbriefhelp.zendesk.com
Webinar Details
#EVENTDAY#, #EVENTDATE#  |  #EVENTTIME# #EVENTTIMEZONESHORT#  |  1 hour
Sponsored by Boehringer Ingelheim
Add to Your Calendar
Use the links below to add to your calendar. We'll also send a couple reminders in advance of the webinar.
#CALENDARREMINDER#
How to Join the Webinar
Click the link below to join the webinar. You can join up to 15 minutes before the start time.
#AUDIENCEURL#
Once you click the link, you may be prompted to sign in with the email you used to register (#EMAIL#).
Thank you for registering! We look forward to seeing you.
Sincerely,
The Clinician's Brief Team
The Boehringer Ingelheim Team